探讨恩格列净对肥胖型2型糖尿病患者血糖、胰岛素抵抗及促代谢因子的影响

Effects of Empagliflozin on Blood Glucose,Insulin Resistance and Pro metabolic Factors in Obese Type 2 Diabetes Mellitus Patients

目的研究恩格列净对肥胖型2型糖尿病(Type 2 Diabetes Mellitus,T2DM)患者血糖、胰岛素抵抗及促代谢因子的影响。方法选取2021年1月-2023年6月福建省建瓯市立医院收治的118例肥胖型T2DM患者为研究对象,按照随机数表法分为观察组和对照组,各59例。对照组使用二甲双胍治疗,观察组除使用二甲双胍外,联合恩格列净进行治疗,两组均持续治疗3个月。比较两组患者的治疗有效率、血糖水平、胰岛功能、促代谢因子水平变化及不良反应发生率。结果治疗后,观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,观察组空腹血糖、餐后2 h血糖水平均低于对照组,差异有统计学意义(P均<0.05)。治疗后,观察组胰岛β细胞功能指数高于对照组,空腹胰岛素、胰岛素抵抗指数水平均低于对照组,差异有统计学意义(P均<0.05)。治疗后,观察组促代谢因子水平低于对照组,差异有统计学意义(P<0.05)。两组治疗期间不良反应发生率比较,差异无统计学意义(P>0.05)。结论恩格列净治疗肥胖型T2DM患者可提升疗效,降低血糖指标水平,调节胰岛功能指标,改善促代谢因子水平,且安全可靠。

Objective To investigate the effects of empagliflozin on blood glucose,insulin resistance and pro-metabolic factors in obese type 2 diabetes mellitus(T2DM)patients.Methods A total of one hundred and eighteen obese T2DM patients admitted to Jian'ou Municipal Hospital of Fujian Province from January 2021 to June 2023 were selected as the study objects,and were divided into observation group and control group according to random number table method,with fifty-nine cases in each group.The control group was treated with metformin,and the observation group was treated with metformin in combination with empagliflozin.Both groups were treated for 3 months.The effec-tive rate,blood glucose level and islet function,the level of pro-metabolic factors and the incidence of adverse reac-tions of the two groups were compared.Results After treatment,the total effective rate of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).After treatment,fasting plasma glucose and 2-hour postprandial plasma glucose levels in the observation group were lower than those in the control group,and the differences were statistically significant(both P<0.05).After treatment,the function index of is-letβcells in observation group was higher than that in control group,and the levels of fasting insulin and insulin resis-tance index were lower than those in control group,and the differences were statistically significant(all P<0.05).After treatment,the level of pro-metabolic factor in the observation group was lower than that in the control group,and the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reac-tions between the two groups(P>0.05).Conclusion In the treatment of obese T2DM patients,empagliflozin can im-prove the therapeutic effect,reduce the level of blood glucose index,regulate the islet function index,and improve the level of pro-metabolic factors,and is safe and reliable.